News

News

Vismodegib named Drug Discovery of the Year by the British Pharmacological Society

Roche announced that the first in class Hedgehog pathway inhibitor vismodegib, was named Drug Discovery of the Year by the British Pharmacological Society.

Read more: Vismodegib named Drug Discovery of the Year by the British Pharmacological Society

"Efficacy and Safety of Vismodegib" Report Released

The New England Journal of Medicine yesterday released a report on the "Efficacy and Safety of Vismodegib in advanced Basal Cell Carcinoma".

Read more: "Efficacy and Safety of Vismodegib" Report Released

Raise money for GORLIN SYNDROME GROUP

Here's a new easy way to raise money for GORLIN SYNDROME GROUP that does not involve parting with extra cash.

Read more: Raise money for GORLIN SYNDROME GROUP

Considering PDT Treatment?

If you are considering Photodynamic Therapy as a treatment for basal cell carcinomas you may be interested in reading all about it.

Read more: Considering PDT Treatment?


 Originally produced by Professor P. A. Farndon, Clinical Geneticist, Jim Costello (deceased) and Margaret Costello.  We are reliant on a team of medical advisors for the clinical content of the website. We are grateful for their continuing support. 
Gorlin Syndrome Group is Registered Charity in the UK - No 1096361 
 
Gorlin Syndrome community on HealthUnlocked
website security